When 16-year-old Clara gave a blood sample as part of a routine brain development study in Munich, she had no idea her DNA would help unravel a hidden thread linking schizophrenia, autism, and insomnia. Her data, along with that of 1,273 other healthy European adolescents in the IMAGEN cohort, has now revealed three genes—MAD1L1, MRPL2, and HLA-DRB1—that appear to sit at the center of a shared biological network influencing six major neuropsychiatric conditions. This discovery, led by researchers from Fudan University, King’s College London, and University Paris-Saclay, marks one of the most comprehensive efforts to date to map the common molecular roots of disorders long treated as entirely separate.
For decades, psychiatry has largely focused on diagnosing and treating conditions like bipolar disorder, ADHD, and major depression through behavioral symptoms alone. But behind the surface, scientists have suspected a deeper biological overlap—especially given how frequently immune dysfunction appears in patients. By analyzing blood-based multi-omics data, including DNA methylation and gene expression, the team identified 73 CpG sites and 62 genes with putative causal roles across disorders. What’s striking is not just the number, but the convergence: three genes emerged as key mediators, with MRPL2 showing methylation changes linked to both schizophrenia and insomnia, and HLA-DRB1—already known for its role in autoimmune regulation—implicated across multiple conditions.
The findings, published in Nature Mental Health, suggest that neuropsychiatric and autoimmune disorders may share a genomic architecture once thought to be unrelated. DNA methylation at site cg06770790, for instance, was found to repress MRPL2 expression, a change associated with increased risk for several conditions. The study’s two-step Mendelian randomization approach strengthens the case for causality, not just correlation. This could transform how we diagnose and treat mental illness—not by symptom clusters, but by targeting shared biological pathways. “The identified genes were significantly enriched in pathways linked to both psychiatric and autoimmune diseases,” the researchers wrote, “suggesting a shared genomic architecture.”
For families navigating multiple diagnoses, this could mean more precise interventions in the future. For clinicians, it opens the door to transdiagnostic treatments—therapies that work across conditions by targeting common mechanisms. While the study focused on adolescents without diagnoses, the biomarkers identified may one day help predict risk long before symptoms appear. As research shifts from siloed categories to shared biology, the line between mental and immune health grows ever thinner. The future of psychiatry may not lie in defining differences, but in understanding what we all share.